Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer's Disease Study (LEADS).
Alzheimer's disease
EOAD
LEADS
amyloid-PET
atypical AD
centiloids
early-onset
sex differences
tau-PET
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
revised:
07
08
2023
received:
14
04
2023
accepted:
08
08
2023
medline:
30
11
2023
pubmed:
10
9
2023
entrez:
10
9
2023
Statut:
ppublish
Résumé
We aimed to describe baseline amyloid-beta (Aβ) and tau-positron emission tomograrphy (PET) from Longitudinal Early-onset Alzheimer's Disease Study (LEADS), a prospective multi-site observational study of sporadic early-onset Alzheimer's disease (EOAD). We analyzed baseline [18F]Florbetaben (Aβ) and [18F]Flortaucipir (tau)-PET from cognitively impaired participants with a clinical diagnosis of mild cognitive impairment (MCI) or AD dementia aged < 65 years. Florbetaben scans were used to distinguish cognitively impaired participants with EOAD (Aβ+) from EOnonAD (Aβ-) based on the combination of visual read by expert reader and image quantification. 243/321 (75.7%) of participants were assigned to the EOAD group based on amyloid-PET; 231 (95.1%) of them were tau-PET positive (A+T+). Tau-PET signal was elevated across cortical regions with a parietal-predominant pattern, and higher burden was observed in younger and female EOAD participants. LEADS data emphasizes the importance of biomarkers to enhance diagnostic accuracy in EOAD. The advanced tau-PET binding at baseline might have implications for therapeutic strategies in patients with EOAD. 72% of patients with clinical EOAD were positive on both amyloid- and tau-PET. Amyloid-positive patients with EOAD had high tau-PET signal across cortical regions. In EOAD, tau-PET mediated the relationship between amyloid-PET and MMSE. Among EOAD patients, younger onset and female sex were associated with higher tau-PET.
Substances chimiques
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
TLA7312TOI
tau Proteins
0
Amyloid beta-Peptides
0
Amyloid
0
Biomarkers
0
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
S98-S114Subventions
Organisme : Alzheimer's Association
ID : ZEN-21-848216
Pays : United States
Organisme : NIA NIH HHS
ID : R56 AG057195
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG062422
Pays : United States
Organisme : NIA NIH HHS
ID : R35 AG072362
Pays : United States
Organisme : NINDS NIH HHS
ID : R21 NS120629
Pays : United States
Organisme : NINDS NIH HHS
ID : U19 NS110456
Pays : United States
Informations de copyright
© 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Zhu XC, Tan L, Wang HF, et al. Rate of early onset Alzheimer's disease: a systematic review and meta-analysis. Ann Transl Med. 2015;3:38. doi:10.3978/j.issn.2305-5839.2015.01.19
Sirkis DW, Bonham LW, Johnson TP, La Joie R, Yokoyama JS. Dissecting the clinical heterogeneity of early-onset Alzheimer's disease. Mol Psychiatry. 2022;27:2674-2688. doi:10.1038/s41380-022-01531-9
Szigeti K, Doody RS. Should EOAD patients be included in clinical trials? Alzheimers Res Ther. 2011;3:4. doi:10.1186/alzrt63
Apostolova LG, Aisen P, Eloyan A, et al. The Longitudinal Early-onset Alzheimer's Disease Study (LEADS): framework and methodology. Alzheimers Dement. 2021;17:2043-2055. doi:10.1002/alz.12350
Swartz JR, Miller BL, Lesser IM, et al. Behavioral phenomenology in Alzheimer's disease, frontotemporal dementia, and late-life depression: a retrospective analysis. J Geriatr Psychiatry Neurol. 1997;10:67-74. doi:10.1177/089198879701000206
Lecanema T. US Veterans Health Administration will cover cost of new Alzheimer's drug. BMJ. 2023;380:628. doi:10.1136/bmj.p628
Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10(3):362-377. doi:10.14283/jpad.2023.30
Jansen WJ, Janssen O, Tijms BM, et al. Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum. JAMA Neurology. 2022;79:228-243. doi:10.1001/jamaneurol.2021.5216
Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 2012;123:1-11. doi:10.1007/s00401-011-0910-3
Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14:535-562. doi:10.1016/j.jalz.2018.02.018
Spina S, La Joie R, Petersen C, et al. Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease. Brain. 2021;144:2186-2198. doi:10.1093/brain/awab099
Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL. Early-onset Alzheimer's disease is associated with greater pathologic burden. J Geriatr Psychiatry Neurol. 2007;20:29-33. doi:10.1177/0891988706297086
La Joie R, Visani AV, Lesman-Segev OH, Baker SL, et al. Association of APOE4 and clinical variability in Alzheimer disease with the pattern of Tau- and Amyloid-PET. Neurology. 2021;96:e650-e661. doi:10.1212/WNL.0000000000011270
Pontecorvo MJ, Devous MD, Navitsky M, et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain. 2017;140:748-763. doi:10.1093/brain/aww334
Stage EC, Svaldi D, Phillips M, et al. Neurodegenerative changes in early- and late-onset cognitive impairment with and without brain amyloidosis. Alzheimers Res Ther. 2020;12:93. doi:10.1186/s13195-020-00647-w
La Joie R, Visani AV, Baker SL, et al. Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET. Sci Transl Med. 2020;12. doi:10.1126/scitranslmed.aau5732
Cho H, Jeon S, Kang SJ, et al. Longitudinal changes of cortical thickness in early- versus late-onset Alzheimer's disease. Neurobiology of Aging. 2013;34(1921):e9-1921.e15. doi:10.1016/j.neurobiolaging.2013.01.004
Cho H, Seo SW, Kim JH, et al. Amyloid deposition in early onset versus late onset Alzheimer's disease. J Alzheimers Dis. 2013;35:813-821. doi:10.3233/JAD-121927
Rabinovici GD, Furst AJ, Alkalay A, et al. Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain. 2010;133:512-528. doi:10.1093/brain/awp326
Ossenkoppele R, Zwan MD, Tolboom N, et al. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement. Brain. 2012;135:2115-2125. doi:10.1093/brain/aws113
Tanner JA, Iaccarino L, Edwards L, et al. Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease. Brain. 2022;145:4489-4505. doi:10.1093/brain/awac229
Klunk WE, Koeppe RA, Price JC, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1-15.e1-4. doi:10.1016/j.jalz.2014.07.003
Jack CR, Wiste HJ, Weigand SD, et al. Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimers Dement. 2017;13:205-216. doi:10.1016/j.jalz.2016.08.005
Ossenkoppele R, Rabinovici GD, Smith R, et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2018;320:1151-1162. doi:10.1001/jama.2018.12917
Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270-279. doi:10.1016/j.jalz.2011.03.008
McKhann GM, Knopman DS, Chertkow, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263-269. doi:10.1016/j.jalz.2011.03.005
Hammers DB, Eloyan A, Taurone A, et al. Profiling baseline performance on the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection. Alzheimer's & Dementia nd;n/a. 2023. doi:10.1002/alz.13160
Townley RA, Graff-Radford J, Mantyh WG, et al. Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes. Brain Commun. 2020;2:fcaa068. doi:10.1093/braincomms/fcaa068
Ossenkoppele R, Pijnenburg YAL, Perry DC, et al. The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. Brain. 2015;138:2732-2749. doi:10.1093/brain/awv191
Gorno-Tempini ML, Dronkers NF, Rankin KP, et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol. 2004;55:335-346. doi:10.1002/ana.10825
Crutch SJ, Schott JM, Rabinovici GD, et al. Consensus classification of posterior cortical atrophy. Alzheimers Dement. 2017;13:870-884. doi:10.1016/j.jalz.2017.01.014
Sabri O, Sabbagh MN, Seibyl J, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. Alzheimers Dement. 2015;11:964-974. doi:10.1016/j.jalz.2015.02.004
Ozlen H, Pichet Binette A, Köbe T, et al. Spatial extent of Amyloid-β levels and associations with Tau-PET and cognition. JAMA Neurol. 2022;79:1025-1035. doi:10.1001/jamaneurol.2022.2442
Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, et al. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain. 2015;138:2020-2033. doi:10.1093/brain/awv112
Maass A, Landau S, Baker SL, et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. Neuroimage. 2017;157:448-463. doi:10.1016/j.neuroimage.2017.05.058
Diedrichsen J, Balsters JH, Flavell J, Cussans E, Ramnani N. A probabilistic MR atlas of the human cerebellum. Neuroimage. 2009;46:39-46. doi:10.1016/j.neuroimage.2009.01.045
Desikan RS, Ségonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31:968-980. doi:10.1016/j.neuroimage.2006.01.021
Royse SK, Minhas DS, Lopresti BJ, et al. Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach. Alzheimers Res Ther. 2021;13:99. doi:10.1186/s13195-021-00836-1
La Joie R, Ayakta N, Seeley WW, et al. Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. Alzheimers Dement. 2019;15:205-216. doi:10.1016/j.jalz.2018.09.001
van der Kall LM, Truong T, Burnham SC, et al. Association of β-Amyloid level, clinical progression, and longitudinal cognitive change in normal older individuals. Neurology. 2021;96:e662-e670. doi:10.1212/WNL.0000000000011222
Sonni I, Lesman Segev OH, Baker SL, et al. Evaluation of a visual interpretation method for tau-PET with 18F-flortaucipir. Alzheimers Dement (Amst). 2020;12:e12133. doi:10.1002/dad2.12133
Wickham H. ggplot2. Springer International Publishing; 2016. doi:10.1007/978-3-319-24277-4
Mowinckel AM, Vidal-Piñeiro D. Visualisation of Brain Statistics with R-packages ggseg and ggseg3d. 2019. doi:10.48550/arXiv.1912.08200
Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid imaging task force, the society of nuclear medicine and molecular imaging, and the Alzheimer's association. Alzheimers Dement. 2013;9:e-1-16. doi:10.1016/j.jalz.2013.01.002
Ossenkoppele R, Leuzy A, Cho H, et al. The impact of demographic, clinical, genetic, and imaging variables on tau PET status. Eur J Nucl Med Mol Imaging. 2021;48:2245-2258. doi:10.1007/s00259-020-05099-w
Yoon B, Guo T, Provost K, et al. Abnormal tau in amyloid PET negative individuals. Neurobiol Aging. 2022;109:125-134. doi:10.1016/j.neurobiolaging.2021.09.019
Krishnadas N, Doré V, Laws SM, et al. Exploring discordant low amyloid beta and high neocortical tau positron emission tomography cases. Assessment & Disease Monitoring. 2022;14:e12326. doi:10.1002/dad2.12326. Alzheimer's & Dementia: Diagnosis.
Chhatwal JP, Schultz SA, McDade E, et al. Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. Lancet Neurol. 2022;21:140-152. doi:10.1016/S1474-4422(21)00375-6
Rosen RF, Ciliax BJ, Wingo TS, et al. Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease. Acta Neuropathol. 2010;119:221-233. doi:10.1007/s00401-009-0583-3
Tomiyama T, Nagata T, Shimada H, et al. A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol. 2008;63:377-387. doi:10.1002/ana.21321
Schöll M, Wall A, Thordardottir S, et al. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology. 2012;79:229-236. doi:10.1212/WNL.0b013e31825fdf18
Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128:755-766. doi:10.1007/s00401-014-1349-0
Tsai RM, Bejanin A, Lesman-Segev O, et al. 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimers Res Ther. 2019;11(1):13. doi:10.1186/s13195-019-0470-7
Soleimani-Meigooni DN, Iaccarino L, La Joie R, et al. 18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases. Brain. 2020;143:3477-3494. doi:10.1093/brain/awaa276
Chételat G, Ossenkoppele R, Villemagne VL, et al. Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. Brain. 2016;139:2528-2539. doi:10.1093/brain/aww159
Landau SM, Horng A, Fero A, Jagust WJ. Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI. Neurology. 2016;86:1377-1385. doi:10.1212/WNL.0000000000002576
Nelson PT, Dickson DW, Trojanowski JQ, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142:1503-1527. doi:10.1093/brain/awz099
Grinberg LT, Heinsen H. Argyrophilic grain disease: an update about a frequent cause of dementia. Dement Neuropsychol. 2009;3:2-7. doi:10.1590/S1980-57642009DN30100002
Gladman JT, Corriveau RA, Debette S, et al. Vascular contributions to cognitive impairment and dementia: research consortia that focus on etiology and treatable targets to lessen the burden of dementia worldwide. Alzheimers Dement (N Y). 2019;5:789-796. doi:10.1016/j.trci.2019.09.017
Doré V, Krishnadas N, Bourgeat P, et al. Relationship between amyloid and tau levels and its impact on tau spreading. Eur J Nucl Med Mol Imaging. 2021;48:2225-2232. doi:10.1007/s00259-021-05191-9
Rowe CC, Doré V, Krishnadas N, et al. Tau Imaging with 18F-MK6240 across the Alzheimer's Disease spectrum. 2022:2022.02.13.22270894. doi:10.1101/2022.02.13.22270894
Pontecorvo MJ, Lu M, Burnham SC, et al. Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurology. 2022;79:1250-1259. doi:10.1001/jamaneurol.2022.3392
Shcherbinin S, Evans CD, Lu M, et al. Association of Amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurology. 2022;79:1015-1024. doi:10.1001/jamaneurol.2022.2793
Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in Early Alzheimer's disease. N Engl J Med. 2021;384:1691-1704. doi:10.1056/NEJMoa2100708
van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's disease. N Engl J Med. 2023;388:9-21. doi:10.1056/NEJMoa2212948
Mummery CJ, Börjesson-Hanson A, Blackburn DJ, et al. Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial. Nat Med. 2023;29:1437-1447. doi:10.1038/s41591-023-02326-3
Reitz C, Rogaeva E, Beecham GW. Late-onset vs nonmendelian early-onset Alzheimer disease. Neurol Genet. 2020;6:e512. doi:10.1212/NXG.0000000000000512
Edwards L, La Joie R, Iaccarino L, et al. Multimodal neuroimaging of sex differences in cognitively impaired patients on the Alzheimer's continuum: greater tau-PET retention in females. Neurobiol Aging. 2021;105:86-98. doi:10.1016/j.neurobiolaging.2021.04.003
Jack CR Jr, Therneau TM, Weigand SD, et al. Prevalence of biologically vs clinically defined Alzheimer spectrum entities using the National Institute on Aging-Alzheimer's Association Research Framework. JAMA Neurology. 2019;76:1174-1183. doi:10.1001/jamaneurol.2019.1971
Ossenkoppele R, Pichet Binette A, Groot C, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med. 2022;28:2381-2387. doi:10.1038/s41591-022-02049-x
Strikwerda-Brown C, Hobbs DA, Gonneaud J, et al. Association of elevated amyloid and tau positron emission tomography signal with near-term development of Alzheimer disease symptoms in older adults without cognitive impairment. JAMA Neurology. 2022;79:975-985. doi:10.1001/jamaneurol.2022.2379
Farrell ME, Jiang S, Schultz AP, et al. Defining the lowest threshold for Amyloid-PET to Predict future cognitive decline and Amyloid accumulation. Neurology. 2021;96:e619-e631. doi:10.1212/WNL.0000000000011214
Salvadó G, Molinuevo JL, Brugulat-Serrat A, et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimers Res Ther. 2019;11:27. doi:10.1186/s13195-019-0478-z
Amadoru S, Doré V, McLean CA, et al. Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer's disease. Alzheimers Res Ther. 2020;12:22. doi:10.1186/s13195-020-00587-5
Bullich S, Roé-Vellvé N, Marquié M, et al. Early detection of amyloid load using 18F-florbetaben PET. Alzheimers Res Ther. 2021;13:67. doi:10.1186/s13195-021-00807-6